Compass Therapeutics Investor Presentation Deck

CTX-009: CRC Patient Demographics and Current Treatments Japan Chemotherapy FOLFOX/FOLFIRI Incident Cases ~50% Metastatic³ 50-70% reach 3L4 1L Treatment Bevacizumab or EGFR inhibitor + chemotherapy US 153,020¹ 38,000-53,000 patients Anti-PD-1 with MSI-H/dMMR mutation ~5% of CRC EU5 1. NCI Surveillance, Epidemiology, and End Results (SEER) program 2. International Agency for Research on Cancer/GLOBOCAN COMPASS 3. L Biller, D Schrag, JAMA 2021 Feb 16 THERAPEUTICS 4. Bekaii-Saab, Clin advances in Hem and Onc, Supp Jan 2021 246,734² 2L Treatment Bevacizumab or EGFR + chemo 148,505² BRAF/EGFR with V600E mutation 5-8% of CRC Worldwide 1,931,590² 3L Treatment Regorafenib ORR 1%, Median PFS 2.0 months Trifluridine/ tipiracil ORR 1-2% Median PFS ~2 months 27

View entire presentation